A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

Following a pilot which involved 10,000 people with non-small cell lung cancer (the most common type), the test is ... “Another red flag is losing weight without changing your eating patterns or your ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An international study, significantly shaped by Greek oncology, has unveiled a promising new treatment for small cell lung cancer (SCLC).

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

The discovery of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) represented a groundbreaking advancement, shifting the treatment paradigm of these diseases ...

Tarlatamab is specific for small cell lung cancer patients who haven’t responded to other treatment. “It’s exciting for these patients because there hasn’t been a lot of good, ...